Home
Orbital Therapeutics

Orbital Therapeutics Market Share Analysis for June 2026

READY TO EXPLORE RNA’S FULL POTENTIAL TOGETHER?

Health > Biotechnology and Pharmaceuticals

Domainorbitaltx.com

Year Founded2022

Employees51 - 200

Annual Revenue$2M - $5M

Orbital Therapeutics

Orbital Therapeutics (including company regionals)

orbitaltx.com

See more website traffic and engagement information

Orbital Therapeutics Revenue up to June 2026 is 2M - 5M

revenue generated by Orbital Therapeutics top domains

Orbital Therapeutics top domains revenue over 3 years

Revenue for Orbital Therapeutics top domains

orbitaltx.com2M - 5M

See more with Sales Intelligence

Total visits to Orbital Therapeutics's top domains

Understand Orbital Therapeutics market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

orbitaltx.com3.6K

See more with Sales Intelligence

Avg. visit duration in Orbital Therapeutics's top domains

Analyze Orbital Therapeutics engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

orbitaltx.com00:00:17

See more with Sales Intelligence

Avg. pageviews on Orbital Therapeutics's top domains

See how Orbital Therapeutics keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

orbitaltx.com1.77

See more with Sales Intelligence

Orbital Therapeutics top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Orbital Therapeutics

These are the website technologies, by industry, used by Orbital Therapeutics top domains

Payment & Currencies (8)

Cart Functionality

Widget (4)

Twemoji

Content Management System (3)

WordPress

Marketing (2)

Google Marketing Platform

More Technologies

8

See all

News & Signals from Orbital Therapeutics

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsOrbital Therapeutics is planning to receive financing of $1.5B.Under the terms of the agreement, Orbital is set to receive $1.5 billion in cash from BMS at closing and is subject to the satisfaction of customary closing conditions.

NewsOrbital Therapeutics is developing RNA platform.Orbital Therapeutics CEO Ron Philip commented: "Since inception, Orbital has made significant strides developing a differentiated RNA platform designed to enable a new generation of RNA medicines that reach more tissues, address more diseases, and benefit more patients.

NewsOrbital Therapeutics is developing RNA medicines that can 'reprogramme' immune cells.Cambridge, Massachusetts-based Orbital is developing RNA medicines that can 'reprogramme' immune cells in the body and direct them to treat diseases.